Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FZACB
ADC Name
B7H3-C1-ADC-21 (DAR4)
Synonyms
B7H3 C1 ADC 21 (DAR4)
   Click to Show/Hide
Organization
Suzhou Medilink Therapeutics Ltd.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Astrocytoma [ICD11:2F36]
Investigative
Kidney cancer [ICD11:2C90-2C91]
Investigative
Melanoma [ICD11:2C30]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
4.5
Structure
Antibody Name
B7H3-C1
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
B7H3-C1-ADC-21(DAR4) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
31.06
ug/mL
NCI-H358 cells
Minimally invasive lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 31.06 ug/mL Positive CD276 expression (CD276 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Minimally invasive lung adenocarcinoma NCI-H358 cells CVCL_1559
References
Ref 1 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.